384 related articles for article (PubMed ID: 30599232)
1. Drug-delivering-drug approach-based codelivery of paclitaxel and disulfiram for treating multidrug-resistant cancer.
Mohammad IS; Teng C; Chaurasiya B; Yin L; Wu C; He W
Int J Pharm; 2019 Feb; 557():304-313. PubMed ID: 30599232
[TBL] [Abstract][Full Text] [Related]
2. A Smart Paclitaxel-Disulfiram Nanococrystals for Efficient MDR Reversal and Enhanced Apoptosis.
Mohammad IS; He W; Yin L
Pharm Res; 2018 Feb; 35(4):77. PubMed ID: 29488114
[TBL] [Abstract][Full Text] [Related]
3. Folic Acid-Modified Nanoerythrocyte for Codelivery of Paclitaxel and Tariquidar to Overcome Breast Cancer Multidrug Resistance.
Zhong P; Chen X; Guo R; Chen X; Chen Z; Wei C; Li Y; Wang W; Zhou Y; Qin L
Mol Pharm; 2020 Apr; 17(4):1114-1126. PubMed ID: 32176509
[TBL] [Abstract][Full Text] [Related]
4. Reconstituted high density lipoprotein mediated targeted co-delivery of HZ08 and paclitaxel enhances the efficacy of paclitaxel in multidrug-resistant MCF-7 breast cancer cells.
Zhang F; Wang X; Xu X; Li M; Zhou J; Wang W
Eur J Pharm Sci; 2016 Sep; 92():11-21. PubMed ID: 27343697
[TBL] [Abstract][Full Text] [Related]
5. Systematic evaluation of multifunctional paclitaxel-loaded polymeric mixed micelles as a potential anticancer remedy to overcome multidrug resistance.
Zhang J; Zhao X; Chen Q; Yin X; Xin X; Li K; Qiao M; Hu H; Chen D; Zhao X
Acta Biomater; 2017 Mar; 50():381-395. PubMed ID: 27956367
[TBL] [Abstract][Full Text] [Related]
6. Co-administration of paclitaxel and 2-methoxyestradiol using folate-conjugated human serum albumin nanoparticles for improving drug resistance and antitumor efficacy.
Liu X; Zhao T; Xu Y; Huo P; Xu X; Zhang Z; Tian Q; Zhang N
Pharm Dev Technol; 2021 Jan; 26(1):1-10. PubMed ID: 32985928
[TBL] [Abstract][Full Text] [Related]
7. Nobiletin potentiates paclitaxel anticancer efficacy in A549/T xenograft model: Pharmacokinetic and pharmacological study.
Feng SL; Tian Y; Huo S; Qu B; Liu RM; Xu P; Li YZ; Xie Y
Phytomedicine; 2020 Feb; 67():153141. PubMed ID: 31884406
[TBL] [Abstract][Full Text] [Related]
8. Reversal of multidrug resistance by co-delivery of paclitaxel and lonidamine using a TPGS and hyaluronic acid dual-functionalized liposome for cancer treatment.
Assanhou AG; Li W; Zhang L; Xue L; Kong L; Sun H; Mo R; Zhang C
Biomaterials; 2015 Dec; 73():284-95. PubMed ID: 26426537
[TBL] [Abstract][Full Text] [Related]
9. Pluronic-based functional polymeric mixed micelles for co-delivery of doxorubicin and paclitaxel to multidrug resistant tumor.
Chen Y; Zhang W; Huang Y; Gao F; Sha X; Fang X
Int J Pharm; 2015 Jul; 488(1-2):44-58. PubMed ID: 25899286
[TBL] [Abstract][Full Text] [Related]
10. Paclitaxel delivered by CD44 receptor-targeting and endosomal pH sensitive dual functionalized hyaluronic acid micelles for multidrug resistance reversion.
Liu Y; Zhou C; Wei S; Yang T; Lan Y; Cao A; Yang J; Hou Y
Colloids Surf B Biointerfaces; 2018 Oct; 170():330-340. PubMed ID: 29936386
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic efficacy and safety of paclitaxel/lonidamine loaded EGFR-targeted nanoparticles for the treatment of multi-drug resistant cancer.
Milane L; Duan Z; Amiji M
PLoS One; 2011; 6(9):e24075. PubMed ID: 21931642
[TBL] [Abstract][Full Text] [Related]
12. Multifunctional mesoporous silica nanoparticles mediated co-delivery of paclitaxel and tetrandrine for overcoming multidrug resistance.
Jia L; Li Z; Shen J; Zheng D; Tian X; Guo H; Chang P
Int J Pharm; 2015 Jul; 489(1-2):318-30. PubMed ID: 25956050
[TBL] [Abstract][Full Text] [Related]
13. IF7-Conjugated Nanoparticles Target Annexin 1 of Tumor Vasculature against P-gp Mediated Multidrug Resistance.
Yu DH; Liu YR; Luan X; Liu HJ; Gao YG; Wu H; Fang C; Chen HZ
Bioconjug Chem; 2015 Aug; 26(8):1702-12. PubMed ID: 26076081
[TBL] [Abstract][Full Text] [Related]
14. Anticancer efficacy and toxicokinetics of a novel paclitaxel-clofazimine nanoparticulate co-formulation.
Koot D; Cromarty D
Drug Deliv Transl Res; 2015 Jun; 5(3):257-67. PubMed ID: 25795051
[TBL] [Abstract][Full Text] [Related]
15. GSH-responsive poly-resveratrol based nanoparticles for effective drug delivery and reversing multidrug resistance.
Liping Y; Jian H; Zhenchao T; Yan Z; Jing Y; Yangyang Z; Jing G; Liting Q
Drug Deliv; 2022 Dec; 29(1):229-237. PubMed ID: 35001781
[TBL] [Abstract][Full Text] [Related]
16. Combinational delivery of hydrophobic and hydrophilic anticancer drugs in single nanoemulsions to treat MDR in cancer.
Ma Y; Liu D; Wang D; Wang Y; Fu Q; Fallon JK; Yang X; He Z; Liu F
Mol Pharm; 2014 Aug; 11(8):2623-30. PubMed ID: 24712391
[TBL] [Abstract][Full Text] [Related]
17. RGD peptide-modified, paclitaxel prodrug-based, dual-drugs loaded, and redox-sensitive lipid-polymer nanoparticles for the enhanced lung cancer therapy.
Wang G; Wang Z; Li C; Duan G; Wang K; Li Q; Tao T
Biomed Pharmacother; 2018 Oct; 106():275-284. PubMed ID: 29966971
[TBL] [Abstract][Full Text] [Related]
18. Delivery of baicalein and paclitaxel using self-assembled nanoparticles: synergistic antitumor effect in vitro and in vivo.
Wang W; Xi M; Duan X; Wang Y; Kong F
Int J Nanomedicine; 2015; 10():3737-50. PubMed ID: 26045664
[TBL] [Abstract][Full Text] [Related]
19. Green design "bioinspired disassembly-reassembly strategy" applied for improved tumor-targeted anticancer drug delivery.
Wang R; Gu X; Zhou J; Shen L; Yin L; Hua P; Ding Y
J Control Release; 2016 Aug; 235():134-146. PubMed ID: 27238442
[TBL] [Abstract][Full Text] [Related]
20. Synergistic Combination of Sodium Aescinate-Stabilized, Polymer-Free, Twin-Like Nanoparticles to Reverse Paclitaxel Resistance.
Li J; Zheng L; Wang R; Sun D; Liang S; Wu J; Liu Y; Tian X; Li T; Yang Y; Han L
Int J Nanomedicine; 2020; 15():5839-5853. PubMed ID: 32848393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
